

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 15, 2025

Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

Company name: FRANCE BED HOLDINGS CO., LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 7840
 URL: <https://francebed-hd.co.jp>
 Representative: Shigeru Ikeda, Representative Director, Chairman and President
 Inquiries: Akihiko Osada, Director (in charge of Accounting/General Affairs Group)
 Telephone: +81-3-6741-5501
 Scheduled date of annual general meeting of shareholders: June 24, 2025
 Scheduled date to commence dividend payments: June 25, 2025
 Scheduled date to file annual securities report: June 23, 2025
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(1) Consolidated operating results

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Fiscal year ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
March 31, 2025	60,561	2.3	4,696	2.3	4,686	0.6	2,946	(5.9)
March 31, 2024	59,151	0.9	4,587	2.3	4,657	3.8	3,134	15.9

Note: Comprehensive income For the fiscal year ended March 31, 2025: ¥3,713 million [9.1%]
 For the fiscal year ended March 31, 2024: ¥3,402 million [54.8%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary profit to total assets	Ratio of operating profit to net sales
Fiscal year ended	Yen	Yen	%	%	%
March 31, 2025	85.28	76.89	7.4	6.7	7.7
March 31, 2024	87.28	86.85	8.2	6.9	7.7

Reference: Share of profit (loss) of entities accounted for using equity method
 For the fiscal year ended March 31, 2025: ¥22 million
 For the fiscal year ended March 31, 2024: ¥34 million

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
March 31, 2025	70,888	40,607	57.2	1,175.06
March 31, 2024	68,575	38,211	55.7	1,106.37

Reference: Equity
 As of March 31, 2025: ¥40,607 million
 As of March 31, 2024: ¥38,211 million

(3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
Fiscal year ended	Millions of yen	Millions of yen	Millions of yen	Millions of yen
March 31, 2025	7,448	(4,929)	(2,498)	13,223
March 31, 2024	7,829	(5,616)	633	13,202

2. Cash dividends

	Annual dividends per share					Total cash dividends (Total)	Payout ratio (Consolidated)	Ratio of dividends to net assets (Consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2024	—	17.00	—	22.00	39.00	1,372	44.6	3.6
Fiscal year ended March 31, 2025	—	17.00	—	23.00	40.00	1,382	46.9	3.5
Fiscal year ending March 31, 2026 (Forecast)	—	17.00	—	24.00	41.00		46.4	

3. Consolidated earnings forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Fiscal year ending March 31, 2026	62,300	2.8	4,750	1.1	4,750	1.3	3,050	3.5	88.25

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

Note: For details, please refer to “(5) Notes Regarding Consolidated Financial Statements (Changes in Accounting Policies)” under 3. Consolidated Financial Statements and Primary Notes on page 20 of the accompanying materials.

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2025	34,747,500 shares
As of March 31, 2024	38,397,500 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2025	189,920 shares
As of March 31, 2024	3,859,837 shares

(iii) Average number of shares outstanding during the period

Fiscal year ended March 31, 2025	34,552,595 shares
Fiscal year ended March 31, 2024	35,907,080 shares

* Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Explanation regarding appropriate use of earnings forecasts, and other special matters

Caution regarding forward-looking statements

This document contains forward-looking statements including performance forecasts based on information available to the Company at the time of disclosure and certain assumptions that the Company believes to be reasonable. The Company makes no assurances as to their outcomes. Actual performance may differ substantially from these forecasts owing to a wide range of factors. For the assumptions underlying the forecasts and precautions when using the forecasts, please refer to 1. Summary of Operating Results, etc.; (4) Future Outlook on page 5 of the accompanying materials.

How to obtain supplementary material on financial results

The Company is scheduled to make a presentation of financial results for institutional investors and securities analysts on Thursday, May 29, 2025. The presentation’s handout materials will be posted on the Company’s website by the day before the presentation.

Attached Material**Index**

1. Summary of Operating Results, etc.	2
(1) Summary of Operating Results for the Fiscal Year Ended March 31, 2025.....	2
(2) Summary of Financial Position for the Fiscal Year Ended March 31, 2025.....	3
(3) Summary of Cash Flows for the Fiscal Year Ended March 31, 2025.....	4
(4) Future Outlook	5
(5) Basic Policy for Profit Distribution, and Dividends in FY2025 and FY2026	5
2. Basic Approach to Selection of Accounting Standards.....	6
3. Consolidated Financial Statements and Primary Notes	7
(1) Consolidated Balance Sheet	7
(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income	10
Consolidated Statement of Income.....	10
Consolidated Statement of Comprehensive Income.....	11
(3) Consolidated Statement of Changes in Equity	12
(4) Consolidated Statement of Cash Flows	14
(5) Notes Regarding Consolidated Financial Statements.....	16
Notes Regarding the Going Concern Assumption.....	16
Basis of Preparation of Consolidated Financial Statements	16
Changes in Accounting Policies	20
Notes Regarding Consolidated Balance Sheet	21
Notes Regarding Consolidated Statement of Income.....	22
Notes Regarding Consolidated Statement of Changes in Equity	22
Notes Regarding Consolidated Statement of Cash Flows	24
Segment Information	24
Per Share Information	27
Significant Subsequent Events	27
4. Other	28

1. Summary of Operating Results, etc.

(1) Summary of Operating Results for the Fiscal Year Ended March 31, 2025

During the fiscal year ended March 31, 2025 (the “period under review”), the Japanese economy saw a trend of gradual recovery against the backdrop of improvement in the employment and income environment and escalating demand from inbound tourists, among others. At the same time, however, the outlook still remains uncertain due to factors such as impacts of the U.S. tariff policies and rising costs resulting from ongoing price increases and higher personnel expenses.

Under these circumstances, the Group formulated a new medium-term management plan encompassing three years beginning in April 2024, and has accordingly been working to create corporate value through sustainability management aimed at realizing a sustainable society, while enhancing its operations by continuing to intensively allocate its management resources in the senior-care business.

In terms of operating results of the Group in the period under review, performance was adversely affected by factors such as rising procurement costs due to the prolonged depreciation of yen, increasing personnel expenses due to wage hikes, and surging distribution costs, but the core welfare equipment rental business achieved robust growth and results from property transactions for hospitals, welfare facilities and hotels were strong. As a result, net sales amounted to 60,561 million yen, up 2.3% year on year, operating profit amounted to 4,696 million yen, up 2.3% year on year, ordinary profit amounted to 4,686 million yen, up 0.6% year on year, and profit attributable to owners of parent amounted to 2,946 million yen, down 5.9% year on year.

Effective from the first quarter of the fiscal year ended March 31, 2025, the fiscal year-end of HOMECARE SERVICE YAMAGUCHI Co., Ltd., a consolidated subsidiary, has been changed from October 31 to March 31 in alignment with the consolidated balance sheet date. Due to this change in the fiscal year-end, the consolidated financial results of the period under review encompass 14 months of profit and loss attributable to said consolidated subsidiary. Further details are presented in “(5) Notes Regarding Consolidated Financial Statements (Basis of Preparation of Consolidated Financial Statements), 3. Fiscal year of the consolidated subsidiaries” under 3. Consolidated Financial Statements and Primary Notes.

The performance of each business segment for the period under review is described below:

(i) Medical Services Business

In the core welfare equipment rental business, amid the increasing population of late elderly persons as the baby-boomer generation turns 75 years or older, we increased our number of bed rentals to elderly persons who need low-level care (needed support condition and condition of need for long-term care level 1) in order to meet the demand for home care for elderly persons who need medium- to high-level care under the long-term care insurance system, and also hired sales personnel to increase the number of continual rental contracts and upgraded our fleet of delivery vehicles. In addition, due to the lack of successors and other recent business succession issues, we focused on gaining rental contracts mainly by strengthening the transfer of customers from welfare equipment rental business operators.

In product development, we persisted with efforts to expand sales of the RaKuDa bed for home-care needs that can be delivered and assembled by one person targeting welfare equipment rental business operators. In addition, we launched sales and rentals in November of the TWIN WAVE TW-80 nursing-care mattress, which is made using the BREATHAIR® material developed by TOYOBO MC Corporation, features a reversible design that allows the sleep comfort to be adjusted, and is also excellent in terms of hygiene.

In regard to hospitals and welfare facilities, in order to achieve greater labor productivity on the nursing care and long-term care frontlines, we focused on sales of IoT-related equipment for reducing workloads and achieving labor savings including beds fitted with the monitoring sensor M-2, and the sleep analysis sensor M-Sleep Bio sensor for detecting heartbeat and respiration to analyze sleep. We also continued our sales promotion activities to put on track the B-to-B rental business with products such as furniture and appliances for elderly care facilities.

As a result, the Medical Services Business recorded net sales of 40,509 million yen, up 4.2% year on year, and ordinary profit of 3,592 million yen, up 1.8% year on year.

(ii) Home Furnishings and Health Business

In the Home Furnishings and Health Business, as consumer sentiment toward durable consumer goods continues to fall alongside ongoing rise in prices and the number of furniture specialty stores in Japan continues to decrease, we focused on sales of high-performance higher-price-bracket products such as the motorized bed series as well as core products that include the LT (LIFE TREATMENT) Mattress premium model, LT LEGACY, mainly through our own showrooms, and in July, we opened the FRANCE BED Gallery Funabashi and the Saitama Showroom in order to increase the number of spaces that showcase the Group's products. Furthermore, in light of the rising percentage of elderly persons in non-urban regions and other factors, we opened the FRANCE BED Nagano Motorized Bed Showroom in November as a new community-based showroom that integrates the Group's two business segments.

Meanwhile, with the aim of increasing sales of our living room products, in May we opened in Minato-ku, Tokyo, our first sofa specialty showroom, which features products of the prominent South Korean JAKOMO sofa manufacturer as the main brand, and also set up JAKOMO Studio in-shop sofa studios at ten of the Group's showrooms in Japan.

In sales for hotels, as number of overseas visitors to Japan reached record level, we generated strong sales amid increasing appetite for capital investment in hotels.

As a result, the Home Furnishings and Health Business posted net sales of 19,481 million yen, down 1.3% year on year, and ordinary profit of 1,067 million yen, down 4.7% year on year.

(2) Summary of Financial Position for the Fiscal Year Ended March 31, 2025

Assets

Total assets increased by 2,313 million yen from the previous year-end to 70,888 million yen as of March 31, 2025. Current assets were up 1,299 million yen to 38,483 million yen from the previous year-end. This was primarily due to decreases of 3,479 million yen in cash and deposits and 205 million yen in notes and accounts receivable - trade and electronically recorded monetary claims - operating, which were partially offset by increases of 4,000 million yen in securities and 851 million yen in inventories. Non-current assets increased by 1,026 million yen from the previous year-end to 32,363 million yen. This result was primarily due to the purchase and depreciation and amortization of property, plant and equipment, and intangible assets, and an increase in retirement benefit asset.

Liabilities

Total liabilities decreased by 82 million yen from the previous year-end to 30,281 million yen. This result was primarily due to decreases of 161 million yen in notes and accounts payable - trade and electronically recorded obligations - operating, 820 million yen in borrowings (including long-term), and 284 million yen in lease liabilities (including long-term), which were partially offset by an increase of 1,198 million yen in income taxes payable.

Net assets

Net assets increased by 2,395 million yen from the previous year-end to 40,607 million yen. This was primarily due to 2,946 million yen of profit attributable to owners of parent and 29 million yen increase from disposal of treasury shares, which was partially offset by a decrease resulting from the 1,347 million yen payment of dividends from surplus.

As a result, the equity-to-asset ratio increased from 55.7% at the previous year-end to 57.2%.

(3) Summary of Cash Flows for the Fiscal Year Ended March 31, 2025

Cash and cash equivalents increased by 20 million yen from the previous year-end to 13,223 million yen as of March 31, 2025. Details of individual cash flow items are as follows:

Cash flows from operating activities

Net cash provided by operating activities amounted to 7,448 million yen, compared with 7,829 million yen for the same period of the previous fiscal year. Operating cash inflows included profit before income taxes of 4,599 million yen, the reporting of depreciation (a non-cash item) of 5,094 million yen, and a decrease in trade receivables of 205 million yen, which were partially offset by cash outflows that included an increase in inventories of 851 million yen, a decrease in trade payables of 161 million yen, and income taxes paid of 900 million yen.

Cash flows from investing activities

Net cash used in investing activities amounted to 4,929 million yen, compared with 5,616 million yen for the same period of the previous fiscal year. Investing cash outflows included purchase of securities of 7,500 million yen and purchase of property, plant and equipment of 4,736 million yen, which were partially offset by cash inflows that included redemption of securities of 7,000 million yen.

Cash flows from financing activities

Net cash used in financing activities amounted to 2,498 million yen, compared with 633 million yen in net cash provided by financing activities for the same period of the previous year. Financing cash outflows included short-term borrowings of 530 million yen, repayments of long-term borrowings of 290 million yen, repayments of finance lease liabilities of 2,995 million yen, and the payment of cash dividends of 1,344 million yen, which were partially offset by cash inflows that included sales and leasebacks of 2,661 million yen.

Reference: Cash flow metrics

	FY2021	FY2022	FY2023	FY2024	FY2025
Equity-to-asset ratio (%)	60.1	58.3	58.9	55.7	57.2
Equity-to-asset ratio at market value (%)	58.3	49.0	58.9	64.8	63.5
Ratio of interest-bearing debt to cash flow (number of years)	1.1	2.5	1.6	1.6	1.6
Interest coverage ratio (times)	159.6	79.9	100.0	95.2	83.1

Equity-to-asset ratio: shareholders' equity / total assets

Equity-to-asset ratio at market value: total market capitalization / total assets

Ratio of interest-bearing debt to cash flow: interest-bearing debt / cash flow

Interest coverage ratio: cash flow / interest payment

Notes: 1. Each indicator has been calculated on the basis of consolidated financial figures.

2. Total market capitalization has been calculated on the basis of the number of shares issued excluding treasury shares.

3. Cash flow refers to cash flows from operating activities.

4. Interest-bearing debt includes all liabilities recorded on the consolidated balance sheet on which interest is paid.

(4) Future Outlook

The future of the Japanese economy is expected to remain uncertain due to the risks of unstable international landscape, and the business environment surrounding our Company is also expected to remain severe, with personnel expenses and logistics costs continuing to rise.

Under these circumstances, the Group will enhance its core welfare equipment rental business by concentrating the management resources owned by the Group into its senior-care business based on the three-year medium-term management plan announced in May 2024, while pursuing sustainability management aimed at realizing a sustainable society.

For our Medical Services Business, in urban areas where we are seeing a significant increase in the population of late elderly people, we will increase our sales staff and conduct M&A, etc. Moreover, in regions where the elderly are dispersed over a wide area, we will focus on wholesale sales such as nursing-care beds. Through these measures, we aim to capture No. 1 share in Japan for the welfare equipment rental business operator market. We will also focus on rental services for general users to meet the rental needs of individuals who are ineligible to use the long-term care insurance system, and on sales of products that contribute to labor-saving against the shortage of human resources for nursing care. Moreover, as measures to build the infrastructure necessary to support business expansion, we are working to continuously invest in rental assets and increase and strengthen service centers with storage and maintenance functions. In addition, we are leveraging AI to optimize delivery routes and digitalize contract documents, and through such promotion of DX, we aim to improve labor productivity and operational efficiency.

For the Home Furnishings and Health Business, amid a decline in the number of furniture specialty stores in Japan, we will focus on product development and sales for e-commerce as well as pursue the optimization of our merchandise supply system to respond to the uncertain market environment.

Additionally, for our overseas business, we will leverage the Group's knowhow accumulated in Japan to deliver high value-added products equipped with our proprietary features to overseas markets such as Vietnam.

Furthermore, by expanding rental services, which are the Group's strength, into all the Group's businesses, we will further increase the sales share of rental sales, and make progress towards sustainability management aimed at realizing a sustainable society.

Accordingly, the Group's consolidated results forecasts for the fiscal year ending March 31, 2026 are net sales of 62,300 million yen, operating profit of 4,750 million yen, ordinary profit of 4,750 million yen, and profit attributable to owners of parent of 3,050 million yen.

(5) Basic Policy for Profit Distribution, and Dividends in FY2025 and FY2026

To maximize its shareholder value, the Company regards profit distribution to shareholders as one of its key management priorities. The Company decides its dividends by comprehensively taking into account its performance, operating environment and the necessity of enhancing its financial soundness in line with its basic policy of making every effort to maintain stable dividend payments.

Based on this policy, the Company plans to pay a year-end dividend of 23.0 yen per share for FY2025, an increase of 1.0 yen from 22.0 yen per share as announced on May 15, 2024.

The Company plans to place this matter on the proposal of the 22nd annual general meeting of shareholders scheduled for June 2025.

Additionally, for FY2026, the Company plans to pay an interim dividend of 17.0 yen per share and a year-end dividend of 24.0 yen per share for an annual dividend of 41.0 yen per share.

2. Basic Approach to Selection of Accounting Standards

The Group applies the J-GAAP as accounting standards to ensure the comparability of its consolidated financial statements from period to period and among entities.

The Group will appropriately respond to the application of the International Financial Reporting Standards (IFRS) upon taking into account circumstances both in Japan and abroad.

3. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheet

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Assets		
Current assets		
Cash and deposits	10,702	7,223
Notes receivable - trade	*3 488	365
Accounts receivable - trade	9,452	9,275
Electronically recorded monetary claims - operating	*3 1,066	1,161
Securities	6,000	10,000
Merchandise and finished goods	5,960	6,517
Work in process	380	454
Raw materials and supplies	2,095	2,315
Other	1,078	1,173
Allowance for doubtful accounts	(40)	(2)
Total current assets	37,184	38,483
Non-current assets		
Property, plant and equipment		
Assets for lease	5,313	5,475
Accumulated depreciation	(3,654)	(3,799)
Assets for lease, net	1,659	1,676
Buildings and structures	18,556	18,753
Accumulated depreciation	(11,990)	(12,485)
Buildings and structures, net	6,566	6,268
Machinery, equipment and vehicles	5,787	5,829
Accumulated depreciation	(4,537)	(4,579)
Machinery, equipment and vehicles, net	1,250	1,249
Tools, furniture and fixtures	3,451	3,550
Accumulated depreciation	(3,014)	(3,160)
Tools, furniture and fixtures, net	436	390
Land	7,211	6,914
Leased assets	14,673	14,531
Accumulated depreciation	(11,035)	(10,813)
Leased assets, net	3,637	3,717
Construction in progress	108	405
Total property, plant and equipment	20,870	20,621
Intangible assets		
Goodwill	691	457
Leased assets	358	204
Software	665	520
Other	20	119
Total intangible assets	1,736	1,301
Investments and other assets		
Investment securities	535	326
Long-term loans receivable	62	52
Deferred tax assets	1,639	1,718
Retirement benefit asset	5,437	7,203
Other	*1 1,137	*1 1,228
Allowance for doubtful accounts	(82)	(89)
Total investments and other assets	8,730	10,440
Total non-current assets	31,336	32,363

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Deferred assets		
Bond issuance costs	53	41
Total deferred assets	53	41
Total assets	68,575	70,888

(Millions of yen)

	As of March 31, 2024	As of March 31, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	*3 2,844	2,666
Electronically recorded obligations - operating	*3 2,002	2,018
Short-term borrowings	2,070	1,540
Current portion of long-term borrowings	290	290
Lease liabilities	2,540	2,322
Income taxes payable	479	1,677
Accrued consumption taxes	235	323
Contract liabilities	234	221
Provision for bonuses	1,567	1,642
Provision for bonuses for directors (and other officers)	17	15
Asset retirement obligations	–	14
Other	2,863	2,813
Total current liabilities	15,144	15,546
Non-current liabilities		
Bonds payable	1,500	1,500
Convertible-bond-type bonds with share acquisition rights	5,049	5,039
Long-term borrowings	4,810	4,520
Lease liabilities	2,064	1,997
Deferred tax liabilities	22	20
Provision for retirement benefits for directors (and other officers)	149	90
Provision for contingent loss	8	8
Retirement benefit liability	446	405
Asset retirement obligations	360	361
Other	808	790
Total non-current liabilities	15,219	14,734
Total liabilities	30,363	30,281
Net assets		
Shareholders' equity		
Share capital	3,000	3,000
Retained earnings	37,755	35,418
Treasury shares	(4,170)	(205)
Total shareholders' equity	36,584	38,213
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(20)	(33)
Deferred gains or losses on hedges	37	(10)
Remeasurements of defined benefit plans	1,609	2,437
Total accumulated other comprehensive income	1,626	2,393
Total net assets	38,211	40,607
Total liabilities and net assets	68,575	70,888

(2) Consolidated Statement of Income and Consolidated Statement of Comprehensive Income
Consolidated Statement of Income

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Net sales	59,151	60,561
Cost of sales	* 27,261	* 27,505
Gross profit	31,889	33,056
Selling, general and administrative expenses	27,302	28,359
Operating profit	4,587	4,696
Non-operating income		
Interest income	8	34
Dividend income	12	7
Share of profit of entities accounted for using equity method	34	22
Compensation income	40	37
Other	136	103
Total non-operating income	233	205
Non-operating expenses		
Interest expenses	83	76
Compensation expenses	36	87
Other	42	52
Total non-operating expenses	163	215
Ordinary profit	4,657	4,686
Extraordinary income		
Gain on sale of non-current assets	8	0
Gain on sale of investment securities	214	—
Total extraordinary income	222	0
Extraordinary losses		
Loss on sale of non-current assets	—	45
Loss on retirement of non-current assets	170	7
Loss on valuation of investment securities	0	16
Loss on sale of investment securities	—	4
Impairment losses	—	14
Total extraordinary losses	171	88
Profit before income taxes	4,708	4,599
Income taxes - current	1,284	2,105
Income taxes - deferred	289	(453)
Total income taxes	1,574	1,652
Profit	3,134	2,946
Profit attributable to owners of parent	3,134	2,946

Consolidated Statement of Comprehensive Income

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Profit	3,134	2,946
Other comprehensive income		
Valuation difference on available-for-sale securities	1	(12)
Deferred gains or losses on hedges	24	(47)
Remeasurements of defined benefit plans, net of tax	242	827
Total other comprehensive income	268	767
Comprehensive income	3,402	3,713
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,402	3,713
Comprehensive income attributable to non-controlling interests	—	—

(3) Consolidated Statement of Changes in Equity

FY2024 (from April 1, 2023 to March 31, 2024)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	3,000	1	38,706	(4,941)	36,766
Changes during period					
Dividends of surplus			(1,333)		(1,333)
Profit attributable to owners of parent			3,134		3,134
Purchase of treasury shares				(2,000)	(2,000)
Disposal of treasury shares		3		14	18
Cancellation of treasury shares		(2,756)		2,756	—
Transfer from retained earnings to capital surplus		2,752	(2,752)		—
Net changes in items other than shareholders' equity					
Total changes during period	—	(1)	(951)	771	(181)
Balance at end of period	3,000	—	37,755	(4,170)	36,584

	Accumulated other comprehensive income				Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	(22)	12	1,367	1,358	38,124
Changes during period					
Dividends of surplus					(1,333)
Profit attributable to owners of parent					3,134
Purchase of treasury shares					(2,000)
Disposal of treasury shares					18
Cancellation of treasury shares					—
Transfer from retained earnings to capital surplus					—
Net changes in items other than shareholders' equity	1	24	242	268	268
Total changes during period	1	24	242	268	87
Balance at end of period	(20)	37	1,609	1,626	38,211

FY2025 (from April 1, 2024 to March 31, 2025)

(Millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity
Balance at beginning of period	3,000	—	37,755	(4,170)	36,584
Changes during period					
Dividends of surplus			(1,347)		(1,347)
Profit attributable to owners of parent			2,946		2,946
Purchase of treasury shares				(0)	(0)
Disposal of treasury shares		4		25	29
Cancellation of treasury shares		(3,940)		3,940	—
Transfer from retained earnings to capital surplus		3,936	(3,936)		—
Net changes in items other than shareholders' equity					
Total changes during period	—	—	(2,336)	3,965	1,628
Balance at end of period	3,000	—	35,418	(205)	38,213

	Accumulated other comprehensive income				Total net assets
	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Remeasurements of defined benefit plans	Total accumulated other comprehensive income	
Balance at beginning of period	(20)	37	1,609	1,626	38,211
Changes during period					
Dividends of surplus					(1,347)
Profit attributable to owners of parent					2,946
Purchase of treasury shares					(0)
Disposal of treasury shares					29
Cancellation of treasury shares					—
Transfer from retained earnings to capital surplus					—
Net changes in items other than shareholders' equity	(12)	(47)	827	767	767
Total changes during period	(12)	(47)	827	767	2,395
Balance at end of period	(33)	(10)	2,437	2,393	40,607

(4) Consolidated Statement of Cash Flows

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Cash flows from operating activities		
Profit before income taxes	4,708	4,599
Depreciation	5,363	5,094
Impairment losses	—	14
Amortization of goodwill	237	234
Loss (gain) on sale of non-current assets	(8)	44
Loss on retirement of non-current assets	170	7
Increase (decrease) in allowance for doubtful accounts	(1)	(30)
Increase (decrease) in provision for bonuses	28	75
Increase (decrease) in provision for bonuses for directors (and other officers)	0	(1)
Increase (decrease) in retirement benefit liability	(61)	(40)
Decrease (increase) in retirement benefit asset	(362)	(539)
Increase (decrease) in provision for retirement benefits for directors (and other officers)	8	(59)
Loss (gain) on sale of investment securities	(214)	4
Loss (gain) on valuation of investment securities	0	16
Interest and dividend income	(21)	(42)
Interest expenses	83	76
Share of loss (profit) of entities accounted for using equity method	(34)	(22)
Decrease (increase) in trade receivables	(499)	205
Decrease (increase) in inventories	(52)	(851)
Increase (decrease) in trade payables	319	(161)
Increase (decrease) in accrued expenses	59	(131)
Other, net	(146)	(87)
Subtotal	9,579	8,403
Interest and dividends received	20	34
Interest paid	(82)	(89)
Income taxes paid	(1,688)	(900)
Net cash provided by (used in) operating activities	7,829	7,448

(Millions of yen)

	Fiscal year ended March 31, 2024	Fiscal year ended March 31, 2025
Cash flows from investing activities		
Purchase of property, plant and equipment	(4,546)	(4,736)
Proceeds from sale of property, plant and equipment	9	319
Purchase of securities	(7,000)	(7,500)
Proceeds from redemption of securities	6,000	7,000
Proceeds from sale of investment securities	234	0
Purchase of shares of subsidiaries and associates	–	(54)
Proceeds from sale of shares of subsidiaries and associates	–	247
Purchase of investments in other securities of subsidiaries and associates	(31)	–
Proceeds from collection of loans receivable	7	9
Purchase of intangible assets	(218)	(214)
Payments for asset retirement obligations	(71)	–
Other, net	1	0
Net cash provided by (used in) investing activities	(5,616)	(4,929)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(480)	(530)
Proceeds from long-term borrowings	1,200	–
Repayments of long-term borrowings	(200)	(290)
Redemption of bonds	(300)	–
Proceeds from issuance of convertible bond-type bonds with share acquisition rights	5,021	–
Purchase of treasury shares	(2,004)	(0)
Proceeds from sale and leaseback transactions	2,188	2,661
Repayments of lease liabilities	(3,460)	(2,995)
Dividends paid	(1,330)	(1,344)
Net cash provided by (used in) financing activities	633	(2,498)
Effect of exchange rate change on cash and cash equivalents	–	–
Net increase (decrease) in cash and cash equivalents	2,846	20
Cash and cash equivalents at beginning of period	10,355	13,202
Cash and cash equivalents at end of period	* 13,202	* 13,223

(5) Notes Regarding Consolidated Financial Statements**Notes Regarding the Going Concern Assumption**

Not applicable

Basis of Preparation of Consolidated Financial Statements

1. Scope of consolidation

(1) Number of consolidated subsidiaries: 8

Names of consolidated subsidiaries:

FRANCE BED CO., LTD.

FRANCE BED FURNITURE CO., LTD.

FRANCE BED SALES CO., LTD.

FB TOMONOKAI CO., LTD.

TOKYO BED CO., LTD.

TSUBASA CO., LTD.

KASHIDASU CO., Ltd.

HEMOCARE SERVICE YAMAGUCHI Co., Ltd.

(2) Names of unconsolidated subsidiaries:

JIANGSU FRANCE BED CO., LTD.

FRANCE BED MEDICAL SERVICE Co., Ltd.

Reason for exclusion from the scope of consolidation

The unconsolidated subsidiaries have been excluded from the scope of consolidation as they are all small in size and their total amounts in terms of total assets, net sales, profit or loss (amount corresponding to equity interest) and retained earnings (amount corresponding to equity interest) do not materially impact the consolidated financial statements.

2. Application of the equity method

(1) Number of affiliates accounted for using equity method:

Not applicable.

Note that in the fiscal year ended March 31, 2025, Mistral Service Co., Ltd. was not accounted for using the equity method following the sales of its shares held by a consolidated subsidiary.

(2) The major unconsolidated subsidiaries and affiliates (JIANGSU FRANCE BED CO., LTD. and FRANCE BED MEDICAL SERVICE Co., Ltd.) are not accounted for using the equity method, as their exclusion has a minor impact on the consolidated financial statements in terms of profit or loss (amount corresponding to equity interest) and retained earnings (amount corresponding to equity interest), and is considered immaterial from the overall perspective.

3. Fiscal year of the consolidated subsidiaries

Effective from the fiscal year ended March 31, 2025, the fiscal year-end of HEMOCARE SERVICE YAMAGUCHI Co., Ltd., a consolidated subsidiary, has been changed from October 31 to March 31 in alignment with the consolidated balance sheet date. Prior to this change, in preparing the consolidated financial statements, financial statements based on provisional results of said consolidated subsidiary as of January 31 were used. However, based on this change in the fiscal year-end, the fiscal period for said consolidated subsidiary during the fiscal year ended March 31, 2025 is to encompass the 14 months between February 1, 2024 and March 31, 2025 due

to this change in the fiscal year-end, and the effect associated with this change in the fiscal year-end has been adjusted through the consolidated statement of income.

Said consolidated subsidiary posted net sales of 415 million yen, operating profit of 71 million yen, ordinary profit of 73 million yen, and profit before income taxes of 72 million yen for the period from February 1, 2024 to March 31, 2024.

4. Notes regarding accounting policies

(1) Valuation standards and methods for important assets

(i) Securities

a. Available-for-sale securities

- Items other than stock, etc. without market price

Stated at market value (The difference in valuation is fully charged to net assets, with the cost of securities sold calculated by the moving average method.)

- Stock, etc. without market price

Stated at cost determined by the moving average method

b. Investments in other securities of subsidiaries and associates

Stated at cost determined by the moving average method

(ii) Derivatives

Stated at market value

(iii) Inventories

a. Merchandise, finished goods and work in process

Stated at cost determined by the first-in, first-out method. (Balance sheet values are calculated by reducing the book values of these assets based on a decline in profitability.)

b. Raw materials and supplies

Stated at cost determined by the last purchase method. (Balance sheet values are calculated by reducing the book values of these assets based on a decline in profitability.)

(2) Depreciation method for important depreciable assets

(i) Property, plant and equipment

The straight-line method is applied.

The estimated useful lives of assets are principally as follows:

Assets for lease	3 to 10 years
Buildings and structures	2 to 50 years
Machinery, equipment and vehicles	2 to 13 years
Tools, furniture and fixtures	2 to 20 years

Assets for lease whose acquisition cost is less than 200,000 yen are equally depreciated over three years as lump-sum depreciable assets.

(ii) Intangible assets

The straight-line method is applied.

Software for internal use is amortized using the straight-line method over the estimated usable period for office use (5 years or 10 years).

(iii) Leased assets

- a. Leased assets related to finance lease transactions that transfer ownership

The same depreciation method applied to non-current assets owned by the Company is applied.

- b. Leased assets related to finance lease transactions that do not transfer ownership

Leased assets related to finance lease transactions not involving the transfer of ownership are depreciated on the straight-line method over the lease period of the leased assets, assuming the lease period as the useful life and no residual value.

(iv) Long-term prepaid expenses

Long-term prepaid expenses are equally amortized over the years.

(3) Accounting standards for significant allowances and provisions

(i) Allowance for doubtful accounts

The allowance for doubtful accounts is provided at an amount of possible losses from accounts receivable - trade and other receivables, based on the historical rate of credit losses for general receivables and on the individual collectability for specific receivables such as receivables with default possibility.

(ii) Provision for bonuses

The provision for bonuses for employees is provided at the amount borne for the fiscal year under review of the estimated amounts to be paid.

(iii) Provision for bonuses for directors (and other officers)

The provision for bonuses for directors (and other officers) is provided at an amount based on the estimated amount to be paid in the fiscal year under review.

(iv) Provision for retirement benefits for directors (and other officers)

The provision for retirement benefits for directors (and other officers) is provided at an amount required to be paid at the end of the fiscal year under review, based on internal rules and regulations.

(v) Provision for contingent loss

The provision for contingent loss is provided at an amount considered necessary, with a reasonable estimate for possible future contingencies.

(4) Method and period of goodwill amortization

Goodwill is amortized equally over the reasonably estimated period of time during which the investment is expected to yield benefits.

(5) Accounting method for retirement benefits

(i) Method for attributing expected retirement benefits to periods of service

In calculating the amount of retirement benefit obligations, the projected benefit method is adopted for attributing estimated retirement benefits over the period up to the end of the fiscal year under review.

(ii) Treatment of actuarial gains or losses

Actuarial gains or losses are amortized using the straight-line method over a certain number of years (primarily 10 years) within the average remaining years of service of the eligible employees at the time of recognition, and allocated proportionately from the fiscal year following the respective fiscal year of recognition.

(iii) Accounting treatment of unrecognized actuarial gains or losses

Unrecognized actuarial gains or losses are recorded after adjustments for tax effects, as remeasurements of defined benefit plans under accumulated other comprehensive income in net assets.

(iv) Adoption of the simplified method by companies that are small in size

Certain consolidated subsidiaries, in the calculation of retirement benefit liability and retirement benefit expenses, apply the simplified method in which the amount to be required at the year-end for voluntary termination is used as retirement benefit obligations.

(6) Accounting standards for significant income and expenses

The Group's main business is the manufacture, rental, retail sale, and wholesale of medical and nursing-care beds and welfare equipment; home renovation; linen supply for hospitals, hotels, and other facilities in the Medical Services Business, as well as the manufacture and wholesale of beds, furniture, bedding, health equipment, and other products in the Home Furnishings and Health Business.

Income related to the sale of merchandise or goods is mainly from wholesale or from sale through manufacturing, etc., and the Group bears a performance obligation to deliver merchandise or goods in accordance with sales contracts concluded with customers. At the moment of delivery of merchandise or goods, the customer gains control over the merchandise or goods and the performance obligation is deemed to be satisfied, with revenue recognized at the time of arrival or acceptance of the merchandise or goods.

For construction contracts, in cases where control over goods or services is transferred to the customer for a certain period of time, we recognize revenue over a certain period of time as we satisfy the performance obligation to transfer goods or services to the customer. For construction contracts in which the period from the date of commencement of transactions to the time when the performance obligation is expected to be fully satisfied is very short, we recognize revenue when the performance obligation has been fully satisfied by applying alternative treatment, without recognizing revenue over a certain period of time.

Rental transactions in the Medical Services Business fall under "lease transactions," which are exempted from the Revenue Recognition Accounting Standard, and thus are not included in the revenue generated from contracts with customers. For certain expenses that were previously recorded as selling, general and administrative expenses and sales discounts that were previously recorded as non-operating expenses, we deduct them from net sales as consideration to be paid to customers.

Consideration for transactions is received within one year of fulfilling the performance obligation and does not include significant financial components.

(7) Significant hedge accounting

(i) Method of hedge accounting

Deferral hedge accounting has been adopted. Designated hedge accounting is applied to certain monetary receivables and payables denominated in foreign currencies hedged by forward exchange.

(ii) Hedging instruments and hedged items

a. Hedging instruments

Derivative transactions (forward exchange contracts)

b. Hedged items

Monetary receivables and payables denominated in foreign currencies exposed to exchange rate fluctuation risk (including foreign currency denominated forecasted transactions).

(iii) Hedging policy

Derivative transactions are conducted mainly for the purpose of hedging the foreign exchange fluctuation risks associated with imports of raw materials and merchandise. In undertaking derivative transactions, they are controlled so that the hedge ratio is maintained to be over a certain level with the planned transaction amount as the maximum limit.

(iv) Method of evaluating hedge effectiveness

a. Prospective test

Verifies whether the transaction is consistent with the “Market Risk Management Rules” and the “Risk Management Guidelines.”

b. Retrospective test

Verifies whether the market and cash flow fluctuations were avoided, for exchange rate fluctuation risk in foreign currency denominated transactions.

(8) Scope of cash and cash equivalents in the consolidated statement of cash flows

Cash and cash equivalents are composed of cash on hand, deposits that can be withdrawn at any time and short-term investments that are readily convertible into cash and face only slight risks of fluctuation in value with redemption due dates arriving within three months from the acquisition date.

(9) Treatment of deferred assets

Bond issuance costs are amortized over the redemption period of the bonds using the straight-line method.

(10) Other significant matters for preparing consolidated financial statements

Accounting for non-deductible consumption taxes

Non-deductible consumption taxes related to non-current assets are treated as periodic expenses attributable to the fiscal year under review.

Changes in Accounting Policies*Application of Accounting Standard for Current Income Taxes, etc.*

The Company has applied the “Accounting Standard for Current Income Taxes” (Accounting Standards Board of Japan (ASBJ) Statement No. 27, October 28, 2022; the “Revised Accounting Standard of 2022”) and other relevant ASBJ regulations from the beginning of the fiscal year ended March 31, 2025.

Revisions to categories for recording current income taxes (taxation on other comprehensive income) conform to the transitional treatment in the proviso of paragraph 20-3 of the Revised Accounting Standard of 2022 and the transitional treatment in the proviso of paragraph 65-2(2) of the “Guidance on Accounting Standard for Tax Effect Accounting” (ASBJ Guidance No. 28, October 28, 2022).

This change in accounting policies has no impact on the consolidated financial statements.

Notes Regarding Consolidated Balance Sheet***1. Pledged assets and secured liabilities**

Assets pledged as collateral are as follows:

(Millions of yen)		
	As of March 31, 2024	As of March 31, 2025
Other (guarantee deposits)	9	9

There are no secured liabilities corresponding to the above assets pledged as collateral.

2. Contingent liabilities (Guarantee obligations)

(1) The Group provides guarantees for the following loans.

(Millions of yen)			
	As of March 31, 2024		As of March 31, 2025
Employees	3	Employees	2

(2) The Group provides guarantees for a lease contract by the following company.

(Millions of yen)			
	As of March 31, 2024		As of March 31, 2025
KASHIDASU CO., Ltd.	—	KASHIDASU CO., Ltd.	34

(3) There is a possibility that the following liability will be incurred in relation to the following company's deposit entrustment contract for the security money for prepaid services.

(Millions of yen)			
	As of March 31, 2024		As of March 31, 2025
FB TOMONOKAI CO., LTD.	527		534

***3. Notes, etc., maturing on consolidated balance sheet date**

Notes, etc., maturing on consolidated balance sheet date are settled on the clearing date. However, since the last day of the fiscal year ended March 31, 2024 was a bank holiday, the following notes, etc. maturing at the fiscal year-end were included in the balance at the end of the fiscal year.

(Millions of yen)			
		As of March 31, 2024	As of March 31, 2025
(Current assets)	Notes receivable - trade	37	—
	Electronically recorded monetary claims - operating	44	—
(Current liabilities)	Notes payable - trade	76	—
	Electronically recorded obligations - operating	6	—

Notes Regarding Consolidated Statement of Income

- * The balance sheet values of inventories reflected a reduction in book value due to a decline in profitability, and the following loss on valuation of inventories was included in cost of sales.

(Millions of yen)

FY2024 (from April 1, 2023 to March 31, 2024)	FY2025 (from April 1, 2024 to March 31, 2025)
64	180

Notes Regarding Consolidated Statement of Changes in Equity

FY2024 (from April 1, 2023 to March 31, 2024)

1. Class and total number of issued shares, and class and number of treasury shares

(Thousand shares)

	Number of shares at beginning of the fiscal year	Increase	Decrease	Number of shares at end of the fiscal year
Issued shares				
Common shares (Note 1)	41,397	–	3,000	38,397
Total	41,397	–	3,000	38,397
Treasury shares				
Common shares (Notes 2, 3)	5,377	1,498	3,016	3,859
Total	5,377	1,498	3,016	3,859

- Notes: 1. The decrease of 3,000 thousand shares in the total number of issued common shares consists of cancellation of treasury shares by resolution of the Board of Directors.
2. The increase of 1,498 thousand shares in the number of common shares held as treasury shares consists of a purchase of 1,498 thousand treasury shares and a purchase of 0 thousand shares representing less than one unit by resolution of the Board of Directors.
3. The decrease of 3,016 thousand shares in the number of common shares held as treasury shares consists of a cancellation of 3,000 thousand treasury shares and a disposal of 16 thousand treasury shares by resolution of the Board of Directors.

2. Dividends

(1) Amounts paid

(Resolution)	Class of shares	Total dividends paid (Millions of yen)	Dividend per share (Yen)	Dividend record date	Effective date
June 23, 2023 Annual general meeting of shareholders	Common shares	720	20.00	March 31, 2023	June 26, 2023
November 10, 2023 Board of Directors' meeting	Common shares	612	17.00	September 30, 2023	December 5, 2023

(2) Dividends for which the record date is during the fiscal year under review, but the effective date is in the following fiscal year

(Resolution)	Class of shares	Total dividends paid (Millions of yen)	Source of dividends	Dividend per share (Yen)	Dividend record date	Effective date
June 25, 2024 Annual general meeting of shareholders	Common shares	759	Retained earnings	22.00	March 31, 2024	June 26, 2024

FY2025 (from April 1, 2024 to March 31, 2025)

1. Class and total number of issued shares, and class and number of treasury shares

(Thousand shares)

	Number of shares at beginning of the fiscal year	Increase	Decrease	Number of shares at end of the fiscal year
Issued shares				
Common shares (Note 1)	38,397	–	3,650	34,747
Total	38,397	–	3,650	34,747
Treasury shares				
Common shares (Notes 2, 3)	3,859	3	3,673	189
Total	3,859	3	3,673	189

- Notes: 1. The decrease of 3,650 thousand shares in the total number of issued common shares consists of cancellation of treasury shares by resolution of the Board of Directors.
2. The increase of 3 thousand shares in the number of common shares held as treasury shares consists of a gratis acquisition of 3 thousand shares through restricted stock-based remuneration and a purchase of 0 thousand shares representing less than one unit.
3. The decrease of 3,673 thousand shares in the number of common shares held as treasury shares consists of a cancellation of 3,650 thousand treasury shares and a disposal of 23 thousand treasury shares by resolution of the Board of Directors.

2. Dividends

(1) Amounts paid

(Resolution)	Class of shares	Total dividends paid (Millions of yen)	Dividend per share (Yen)	Dividend record date	Effective date
June 25, 2024 Annual general meeting of shareholders	Common shares	759	22.00	March 31, 2024	June 26, 2024
November 8, 2024 Board of Directors' meeting	Common shares	587	17.00	September 30, 2024	December 5, 2024

- (2) Dividends for which the record date is during the fiscal year under review, but the effective date is in the following fiscal year

The following matters are to be resolved.

(Resolution)	Class of shares	Total dividends paid (Millions of yen)	Source of dividends	Dividend per share (Yen)	Dividend record date	Effective date
June 24, 2025 Annual general meeting of shareholders	Common shares	794	Retained earnings	23.00	March 31, 2025	June 25, 2025

Notes Regarding Consolidated Statement of Cash Flows

- * Reconciliation of closing balance of cash and cash equivalents and the related account on the consolidated balance sheet

	(Millions of yen)	
	FY2024 (from April 1, 2023 to March 31, 2024)	FY2025 (from April 1, 2024 to March 31, 2025)
Cash and deposits	10,702	7,223
Securities	6,000	10,000
Designated joint operating money trust, etc. with maturities of more than three months when purchased	(3,500)	(4,000)
Cash and cash equivalents	13,202	13,223

Segment Information

1. Summary of reporting segments

The reportable segments of the Group are components of the Group for which discrete financial information is available and regularly reviewed by the Board of Directors to make decisions about allocation of managerial resources and to assess their performance.

The Group identifies the business segments based on similarities in the goods and services provided and other factors. It has two reporting segments: the Medical Services Business, and the Home Furnishings and Health Business.

The main goods and services of each reporting segment are as follows.

Medical Services: Manufacture, procurement, rental, retail sale and wholesale of medical and nursing-care beds and welfare equipment, and linen supply for hospitals, hotels, and other facilities

Home Furnishings and Health: Manufacture, procurement, wholesale and door-to-door sale of beds, furniture, bedding, health appliances, and other products, and advertising and setting up of exhibition venues

2. Method of calculating net sales, profit (loss), assets and other items by reporting segment

The accounting method for the business segments that are reportable is the same as described in “Basis of Preparation of Consolidated Financial Statements.”

Profit figures for reporting segments are expressed in terms of ordinary profit.

Intersegment revenue or transfers are based on actual market price.

3. Information on net sales, profit (loss), assets and other items by reporting segment
FY2024 (from April 1, 2023 to March 31, 2024)

(Millions of yen)

	Reporting segment			Other (Note 1)	Total	Adjustments (Note 2)	Carrying amount (Note 3)
	Medical Services	Home Furnishings and Health	Total				
Net sales							
Sales to external customers	38,862	19,740	58,603	548	59,151	–	59,151
Internal sales among segments or transfers	6	270	277	7	285	(285)	–
Total	38,869	20,011	58,881	555	59,437	(285)	59,151
Segment profit	3,526	1,121	4,647	3	4,650	6	4,657
Segment assets	45,191	25,505	70,696	783	71,480	(2,905)	68,575
Other items							
Depreciation	4,782	557	5,339	16	5,356	6	5,363
Impairment losses	–	–	–	–	–	–	–
Increase in property, plant and equipment and intangible assets	4,624	280	4,905	–	4,905	–	4,905

FY2025 (from April 1, 2024 to March 31, 2025)

(Millions of yen)

	Reporting segment			Other (Note 1)	Total	Adjustments (Note 2)	Carrying amount (Note 3)
	Medical Services	Home Furnishings and Health	Total				
Net sales							
Sales to external customers	40,509	19,481	59,990	571	60,561	–	60,561
Internal sales among segments or transfers	1	313	315	12	327	(327)	–
Total	40,511	19,794	60,306	583	60,889	(327)	60,561
Segment profit	3,592	1,067	4,660	4	4,664	22	4,686
Segment assets	48,207	25,424	73,632	826	74,458	(3,570)	70,888
Other items							
Depreciation	4,535	537	5,072	14	5,087	6	5,094
Impairment losses	–	–	–	14	14	–	14
Increase in property, plant and equipment and intangible assets	4,637	306	4,944	0	4,944	–	4,944

Notes: 1. The “Other” segment is a business segment not included in any of the reporting segments and includes such businesses as real estate leasing.

2. The details of “Adjustments” are as follows:

Segment profit

(Millions of yen)

	FY2024	FY2025
Elimination of inter-segment transactions	1,506	1,576
Corporate revenue and expenses*	(1,499)	(1,554)
Total	6	22

* Corporate revenue and expenses are primarily revenue and expenses that do not belong to the reporting segments pertaining to the company submitting the consolidated financial statements.

Segment assets

(Millions of yen)

	FY2024	FY2025
Elimination of inter-segment transactions	(22,684)	(23,771)
Corporate assets*	19,779	20,201
Total	(2,905)	(3,570)

* Corporate assets are primarily assets that do not belong to the reporting segments pertaining to the company submitting the consolidated financial statements.

3. Segment profit is adjusted to be consistent with ordinary profit reported in the consolidated financial statements.

Per Share Information

(Yen)

	FY2024 (from April 1, 2023 to March 31, 2024)	FY2025 (from April 1, 2024 to March 31, 2025)
Net assets per share	1,106.37	1,175.06
Basic earnings per share	87.28	85.28
Diluted earnings per share	86.85	76.89

Note: The basis for calculating basic earnings per share and diluted earnings per share is as follows:

	FY2024 (from April 1, 2023 to March 31, 2024)	FY2025 (from April 1, 2024 to March 31, 2025)
Basic earnings per share		
Profit attributable to owners of parent (Millions of yen)	3,134	2,946
Amount not attributable to common shareholders (Millions of yen)	—	—
Profit attributable to owners of parent relating to common shares (Millions of yen)	3,134	2,946
Average number of common shares outstanding during the fiscal year (Thousand shares)	35,907	34,552
Diluted earnings per share		
Adjustments to profit attributable to owners of parent (Millions of yen)	(0)	(6)
(Interest expenses included in the above, after deducting the amount equivalent to taxes) (Millions of yen)	(0)	(6)
Increase in the number of common shares (Thousand shares)	175	3,678
(Convertible-bond-type bonds with share acquisition rights included in the above) (Thousand shares)	175	3,678
Summary of potentially dilutive shares not included in the calculation of diluted earnings per share due to the absence of dilutive effects	—	—

Significant Subsequent Events

Not applicable

4. Other

(1) Changes in officers

(i) Change in representative

Not applicable

(ii) Changes in other officers

Directors who are not Audit and Supervisory Committee Members to resign

Yoshiro Yoshino, Director (presently in charge of Corporate Planning Group and Director and Managing Executive Officer, Manager, Medical Business Headquarters, FRANCE BED CO., LTD.)

(iii) Scheduled resignation date

June 24, 2025